Allergan’s Oral CGRP Inhibitor Ubrelvy Approved For Migraine Attacks

 
• By Mandy Jackson
  
FDA Approved
The US FDA approved Allergan's oral CGRP inhibitor Ubrelvy on 23 December.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip